Use of mitoxantrone liposome for treating non-Hodgkin's lymphoma

Disclosed is a use of a liposomal pharmaceutical preparation of mitoxantrone in the preparation of a medicament for treating lymphoma, wherein the lymphoma is preferably non-Hodgkin's lymphoma, further preferably aggressive non-Hodgkin's lymphoma, more preferably diffuse large B-cell lymphoma or peripheral T-cell lymphoma, and more further preferably relapsed or refractory diffuse large B-cell lymphoma or peripheral T-cell lymphoma. The mitoxantrone liposomes are used as single anti-tumor therapeutic agent without being combined with other anti-tumor agents..

Medienart:

Patent

Erscheinungsjahr:

2023

Erschienen:

2023

Enthalten in:

Europäisches Patentamt - (2023) vom: 21. Feb. Zur Gesamtaufnahme - year:2023

Sprache:

Englisch

Beteiligte Personen:

LI CHUNLEI [VerfasserIn]
PENG YUEYING [VerfasserIn]
LOU KUN [VerfasserIn]
WANG YAJUAN [VerfasserIn]
WANG YUMEI [VerfasserIn]
CHEN SHAN [VerfasserIn]
MENG ZHIBIN [VerfasserIn]
XUE JIANFEI [VerfasserIn]
YUAN JING [VerfasserIn]
LUO HONGMEI [VerfasserIn]
YAO XUEKUN [VerfasserIn]
WANG SHIXIA [VerfasserIn]

Links:

Volltext [kostenfrei]

Themen:

Sonstige Themen:
615
A61K: Preparations for medical, dental, or toilet purpose (...)
A61P: Specific therapeutic activity of chemical compounds (...)
che

Anmerkungen:

Source: www.epo.org (no modifications made), First posted: 2023-02-21, Last update posted on www.tib.eu: 2024-02-22, Last updated: 2024-03-01

Patentnummer:

US11583508

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

EPA016412230